Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | DUT | P33316 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1468886 | 0.83 | L3MBTL1 (0.47) | TYMPCRBNL3MBTL1POLBHSD17B10 | |
| SCHEMBL2976955 | 0.79 | CRBN (0.48) | CRBNDDB1KDM4ELMNAPKM | |
| SCHEMBL4712434 | 0.78 | TSHR (0.54) | TYMPTSHRRAB9AL3MBTL1KDM4E | |
| SCHEMBL28132697 | 0.77 | CRBN (0.47) | TYMPCRBNDDB1KDM4ELMNA | |
| SCHEMBL27581645 | 0.77 | CRBN (0.50) | CRBNDDB1LMNAPKMDUT | |
| SCHEMBL10953746 | 0.77 | CRBN (0.50) | CRBNDDB1LMNAPKMDUT | |
| SCHEMBL11560902 | 0.76 | TSHR (0.47) | TYMPTSHRRAB9AL3MBTL1KDM4E | |
| SCHEMBL108176 | 0.76 | CRBN (0.46) | CRBNDDB1KDM4ELMNAPKM | |
| SCHEMBL16057473 | 0.73 | POLB (0.43) | TYMPCRBNDDB1POLBHSD17B10 | |
| SCHEMBL7056290 | 0.73 | CRBN (0.52) | CRBNDDB1LMNAPKMDUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58198500-A | — | — | None | — | — | JP | disclosed |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2026-04-16 | — | — | US | disclosed |
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| CN-112105625-B | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | 赛诺菲 | 2024-12-31 | — | — | CN | disclosed |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | SANOFI SA (FR) | 2024-11-14 | — | — | US | disclosed |
| EP-4373935-A1 | UNC13A ANTISENSE OLIGONUCLEOTIDES | Acurastem, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-4359532-A2 | PIKFYVE ANTISENSE OLIGONUCLEOTIDES | AcuraStem Incorporated (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2024064854-A2 | COMPOUNDS AND METHODS FOR REDUCING MECP2 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | SANOFI (FR) | 2024-02-13 | — | — | US | disclosed |
| EP-4301766-A1 | PURIFICATION METHODS FOR OLIGOMERIC COMPOUNDS | Ionis Pharmaceuticals, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2006113204-A2 | THYMIDINE DERIVATIVES FOR TREATMEMT OF KAPOSI'S SARCOMA | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1701727-A1 | DUTPASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005097757-A2 | NUCLEOSIDE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222185-A1 | Nucleoside derivatives and therapeutic uses therof | REXAHN CORPORATION (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005065689-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| WO-2003018577-A1 | ANTIVIRAL NUCLEOSIDE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | POSTECH FOUNDATION (KR) | 2003-03-06 | — | — | WO | disclosed |
| EP-0827498-A1 | NEW ANTIVIRAL SUBSTITUTED PYRIMIDINEDIONE HOMOCARBOCYCLIC NUCLEOSIDE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENTS | Samjin Pharmaceutical Co., Ltd. (KR) | 1998-03-11 | — | — | EP | disclosed |
| WO-1998005662-A1 | CONFORMATIONALLY LOCKED NUCLEOSIDE ANALOGS AS ANTIHERPETIC AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997030979-A1 | NEW ANTIVIRAL SUBSTITUTED PYRIMIDINEDIONE HOMOCARBOCYCLIC NUCLEOSIDE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENTS | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 1997-08-28 | — | — | WO | disclosed |
| JP-S58198500-A | RIBONUCLEOSIDE SUBSTITUTED WITH 4-METHOXYBENZYL GROUP IN THE 2'-POSITION | MITSUI TOATSU CHEM INC | 1983-11-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897911-B2 | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same | RNMT, RRM2B, RRM2 | TYMP 138/4885CRBN 1552/4885TSHR 1805/4885 |
| US-20050222185-A1 | Nucleoside derivatives and therapeutic uses therof | TYMP, NUDT1, HPRT1 | TYMP 1/4885CRBN 3367/4885TSHR 3932/4885 |
| US-20260103480-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | NSUN2, NSUN3, SNRPA | TYMP 511/4885CRBN 648/4885TSHR 1010/4885 |
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | RNMT, RNGTT, NSUN2 | TYMP 67/4885CRBN 3589/4885TSHR 3990/4885 |
| US-20240376137-A1 | NUCLEOTIDE PRECURSORS, NUCLEOTIDE ANALOGS AND OLIGOMERIC COMPOUNDS CONTAINING THE SAME | RNMT, NSUN2, ADAR | TYMP 123/4885CRBN 1601/4885TSHR 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.